Durvalumab
跳至導覽
跳至搜尋
Immunotherapy: mechanism of action for Durvalumab， Pembrolizumab，Ipilimumab， Atezolizumab 。Adapted from: First line Immunotherapy for Non-Small Cell Lung Cancer。 Nasser NJ， Gorenberg M， Agbarya A。 Pharmaceuticals 2020， 13(11)， 373 https://doi.org/10.3390/ph13110373
Durvalumab [1]
註解 [修改]
- ↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (Iⁿ). Proposed Iⁿ: List 112" (PDF). WHO Drug Information. 28 (4). goân-loē-iông (PDF) tī 28 August 2021 hőng khó͘-pih. 6 September 2022 khòaⁿ--ê. Unknown parameter
|url-status=ignored (help) - ↑ "Durvalumab (Imfinzi)". U.S. Food and Drug Administration (FDA). goân-loē-iông tī 8 May 2017 hőng khó͘-pih. 2017-05-06 khòaⁿ--ê. Unknown parameter
|url-status=ignored (help) - ↑ Syn NL，丁MW， Mok TS，蘇RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439. Vancouver style error: initials (help)
參閱 [修改]
- Atezolizumab (Tecentriq)
- Avelumab (Bavencio)
外部 連結 [修改]
- "Durvalumab". NCI Drug Dictionary. National Cancer Institute.
- "Durvalumab". National Cancer Institute. 5 May 2017.
| ||||||||||||||||||||||
